Royal Biologics Unveils FDA-Approved Fibrinet® PRF Wound Matrix for Effective Wound Management

Royal Biologics Introduces Innovative Wound Care Solution

On April 7, 2026, Royal Biologics, a prominent name in regenerative medicine, announced a groundbreaking achievement: the FDA clearance of their Fibrinet® PRF Wound Matrix for the management of exuding cutaneous wounds. This innovation represents a significant advancement in wound care, particularly for patients suffering from diabetic and venous ulcers.

What is Fibrinet® PRF Wound Matrix?

Fibrinet® PRF Wound Matrix is an advanced point-of-care system that utilizes a patient’s own platelets, concentrating them into a durable Platelet-Rich Fibrin Matrix (PRFM). The use of this system allows healthcare professionals to create a personalized fibrin scaffold directly at the wound site, which can expedite the healing process by leveraging the body’s natural healing capabilities. Unlike traditional wound care methods that rely heavily on external substances or treatments, the Fibrinet® system empowers clinicians to harness the patient’s biological material for improved outcomes.

This device can be easily administered under the supervision of healthcare professionals, allowing for the PRFM matrix to be applied directly onto diabetic ulcers, venous ulcers, or even wounds that have undergone mechanical or surgical debridement.

The Impact of FDA Approval

The FDA clearance is a crucial milestone as it not only signifies that the Fibrinet® PRF Wound Matrix meets stringent safety and efficacy standards but also aligns with the Centers for Medicare & Medicaid Services (CMS) policies. Specifically, the CMS maintains National Coverage Determination NCD 270.3, covering PRP devices for wound management. This endorsement enables the Fibrinet® PRF Wound Matrix to be recognized within a competitive landscape filled with numerous PRP devices available in the market, many of which lack such clearances.

Salvatore Leo, the CEO and founder of Royal Biologics, expressed excitement about the approval. He highlighted that Fibrinet® stands out among traditional platelet preparations by producing a platelet-rich fibrin membrane without exogenous activators like bovine thrombin. This results in an effective delivery mechanism for autologous platelets and associated growth factors, further enhancing the healing matrix’s efficacy.

Superior Characteristics of Fibrinet® PRF Wound Matrix

Fibrinet® has been developed through extensive research, with preclinical studies demonstrating its ability to maintain high concentrations of key growth factors for extended periods—some models indicating sustained growth factors for up to seven days. This innovative technology incorporates three main aspects essential for proper tissue repair:
1. Scaffold: An enduring fibrin structure that provides mechanical support to the wound while remaining easily suturable.
2. Signals: Prolonged concentrations of platelet-derived growth factors that promote angiogenesis, cellular recruitment, and overall tissue repair.
3. Cells: High retention rates of intact, viable platelets that ensure ongoing biological activity within the fibrin matrix over time.

The user-friendly nature of the Fibrinet® system allows clinicians to produce the matrix at the point of care using a straightforward workflow, which seamlessly integrates into existing wound care protocols.

Clinical Efficacy

Clinical studies supporting the efficacy of the Fibrinet® PRF technology have shown promising outcomes. An astonishing 92% of treated wounds achieved a reduction of ≥ 50% in wound size within a specified timeframe, and 57% of wounds achieved complete closure within 12 weeks. The average time to heal was reported at approximately 6.75 weeks, demonstrating a remarkable response to treatment.

Availability and Future Developments

Fibrinet® PRF Wound Matrix comes in various configurations, catering to different wound sizes—specifically, the Single Kit for wounds up to 6 cm² and the Double Kit for those extending to 12 cm². Royal Biologics plans to launch the product commercially at the upcoming National Symposium for Advanced Wound Care (SAWC) in Charlotte, NC, allowing attendees to explore the technology in person at Booth #1033.

Conclusion

Royal Biologics maintains its reputation as a leader in orthobiologics and wound care through this innovative offering. Their commitment to delivering high-quality, effective biologic solutions underscores the importance of patient well-being and addresses complex medical needs effectively. For further information about their products and services, visit www.royalbiologics.com.